Absci reports positive interim Phase 1 data for ABS-201; completes $100M offering

Absci Corp

Positive interim Phase 1 data for ABS-201: well tolerated, half-life ≥65 days, supports 2-3 doses/6 months.
Completed $100M underwritten offering incl. $40M strategic investment from Eli Lilly; net proceeds $93.6M.
Cash and securities $201.1M at 6/30/26, up from $125.7M at 3/31/26; runway into H2 2028.
Q2 2026: revenue $0.3M (vs $0.6M YoY); net loss $33.2M (vs $30.6M YoY).
ABS-201 endometriosis Phase 2 planned Q4 2026; PHL proof-of-concept data H2 2026.

Featured in Daily 8-K Digest

Selected #6 for 2026-08-11. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.